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Traditionally, Crohn’s disease has been associated with a
Th1 cytokine profile, while Th2 cytokines are modulators
of ulcerative colitis. This concept has been challenged by
the description of tolerising regulatory T cells (Treg) and
by proinflammatory Th17 cells, a novel T cell population
characterised by the master transcription factor RORct,
the surface markers IL23R and CCR6, and by production
of the proinflammatory cytokines IL17A, IL17F, IL21, IL22
and IL26, and the chemokine CCL20. Th17 cells
differentiate under the influence of IL1b, IL6, IL21 and
IL23. Recent studies indicate that TGFb is essential not
only for the development of murine Th17 cells but also for
differentiation of human Th17 cells. TGFb reciprocally
regulates the differentiation of inflammatory Th17 cells
and suppressive Treg subsets, with the concomitant
presence of proinflammatory cytokines favouring Th17 cell
differentiation. Several studies demonstrated an important
role of Th17 cells in intestinal inflammation, particularly in
Crohn’s disease. Genome-wide association studies indi-
cate that IL23R and five additional genes involved in Th17
differentiation (IL12B, JAK2, STAT3, CCR6 and TNFSF15)
are associated with susceptibility to Crohn’s disease and
partly also to ulcerative colitis. Taken together, both Th1
and Th17 cells are important mediators of inflammation in
Crohn’s disease, although activities previously ascribed to
IL12 may be mediated by IL23. Anti-IL12/IL23p40
antibody therapy, which targets both Th1 and Th17 cells,
is effective in Crohn’s disease. However, the complex
relationship between Th1 and Th17 cells has not been
completely analysed. This will be of great importance to
delineate the specific contributions of these cells to
Crohn’s disease and other autoimmune diseases.
Crohn’s disease and ulcerative colitis are the two
main disease entities of inflammatory bowel
diseases (IBDs). Although their exact aetiology is
still not completely understood, it has been
proposed that their pathogenesis is characterised
by an exaggerated immune response in genetically
susceptible individuals.1 Two decades ago, two T
helper (Th) cell subsets were described.2 For many
years it has been assumed that Crohn’s disease is
mainly mediated by Th1 cells, while ulcerative
colitis is a Th2-like type of inflammation. This has
been supported by increased levels of Th1 cyto-
kines such as interferon c (IFNc) and interleukin 12
(IL12) in Crohn’s disease and an increased expres-
sion of certain Th2 cytokines such as IL13 in
ulcerative colitis.3–5
Th1 cells produce IFNc and their primary role is
the protection against intracellular microbes (fig 1).
Th2 cells produce IL4, IL5 and IL13 and they are
involved in allergic disorders and protection against
extracellular pathogens including gastrointestinal
nematodes (fig 1). Th1 and Th2 cell development
are under the control of certain transcription
factors including T box expressed in T cells (T-
bet) and signal transducer and activator of tran-
scription (STAT) 4 for Th1 cells and GATA-
binding protein (GATA)-3 and STAT6 for Th2
cells6 (fig 1). Th1 differentiation is mainly driven
by IL12 and IFNc, while IL4 (in the absence of
IL12) drives Th2 differentiation.7
Recently, a number of other T cell populations
were discovered, of which regulatory T cells (Treg)
and Th17 cells are the most prominent (fig 1). Treg
cells are important for the control of immune
responses to self-antigens preventing autoimmu-
nity and maintaining self-tolerance. In contrast,
IL17-producing Th17 cells were recognised as novel
group of T cells which play a major role in
autoimmunity. The intestinal immune system
has to maintain both a state of tolerance toward
intestinal antigens and the ability to combat
pathogens. This balance is achieved by a number
of mechanisms including reciprocal regulation of
proinflammatory, effector CD4+ cells and toleris-
ing, suppressive Treg subsets. In Crohn’s disease,
this balance is lost and the effects of proinflamma-
tory T cells outnumber the tolerising, anti-inflam-
matory effects of Treg cells (fig 2). Several studies
indicated that, in addition to Th1 cells, Th17 cells
also play a major role in the pathogenesis of
Crohn’s disease. The important role of Th17 cells,
which express the IL23 receptor (IL23R) on their
surface, in the pathogenesis of Crohn’s disease is
also supported by recent genome-wide association
studies, demonstrating IL23R and other genes
involved in the differentiation of Th17 cells as
IBD susceptibility genes.8–11 Therefore, the previous
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concept of the Th1 and Th2 cell paradigm in IBD has
to be revised and up-dated.
THE ROLE OF TH1 CELLS IN THE PATHOGENESIS OF
CROHN’S DISEASE
Data gathered before the full characterisation of
Th17 cells implicated Th1 cells as the main
mediators of the pathogenesis of Crohn’s disease.
This was based on a number of observations,
including the increased production of IL12 in
macrophages in Crohn’s disease.3 13 14 Moreover,
nuclear extracts from T cells isolated from
inflamed Crohn’s disease lesions contain high levels
of activated STAT4 and T-bet, Th1-associated
transcription factors indicative of IL12 signalling.15
Furthermore, in the mucosa of patients with
Crohn’s disease, there is an enhanced production
of IL18, a cytokine involved in perpetuating Th1
cell responses.16 17 In addition, T cells isolated from
areas with active Crohn’s disease express increased
levels of the IL12Rb2 chain,18 which is character-
istic for Th1 cells, and increased amounts of the
Th1 cytokine IFNc together with decreased levels
of the Th2 cytokine IL4 compared to T cells isolated
from controls.3 19 IFNc-secreting lamina propria
lymphocytes are abundant in the mucosa of patients
with Crohn’s disease. Particularly at onset of
Crohn’s disease, mucosal T cells appear to mount a
typical Th1 response that resembles an acute
infectious process, and is lost with progression to
late Crohn’s disease.20 In addition, clinical response
was observed in a subcohort of patients with
Crohn’s disease treated with an anti-IFNc anti-
body.21 A key role for IFNc has also been shown in a
murine transfer colitis model which did not develop
after transfer of T cells from IFNc knockout mice,22
while over-expression of the Th1-related transcrip-
tion factor STAT4 causes colitis.23
THE ROLE OF IL23 AND TH17 CELLS IN INTESTINAL
INFLAMMATION
The most potent Th1-polarising cytokine is IL12,
composed of the p40 and p35 subunits. However,
its functional role has to be partly re-evaluated
given that many studies used antibodies directed
against the IL12/IL23p40 subunit, which is also
part of the IL23 heterodimer, which is composed of
p40 and the unique subunit p19. Studies in
autoimmune models traditionally recognised as
Th1 disease models revealed that tissue inflamma-
tion did not develop in mice deficient in the
IL23p19 subunit, while inflammation was seen in
IL12p35-deficient mice24 25 suggesting that these
models of autoimmunity are linked to Th17 and not
primarily Th1 responses. Similar observations were
made in models of intestinal inflammation. Hue et al
demonstrated that IL23p19 antibodies suppress
chronic intestinal inflammation in T cell-deficient
Helicobacter hepaticus-infected RAG knockout mice.26
These findings were supported by the results of a
transfer colitis model. In that model recipient mice
deficient in IL23p19 and IL12/IL23p40 are protected
against colitis, while mice deficient for the IL12-
specific subunit p35 were not protected against
colitis.27 This clearly indicates a more important role
for IL23-driven Th17 cytokines than for IL12-driven
Th1 cytokines in these mouse models of intestinal
inflammation. Similarly, CD40-induced colitis
depended on IL23p19 secretion, while IL12p35
secretion controlled wasting disease and serum
cytokine production but not mucosal immuno-
pathology.28 In agreement, Yen et al demonstrated
that colitis in IL10-deficient mice was dependent on
IL23 rather than IL12, further supporting the role of
IL23-driven Th17 cytokines in intestinal inflamma-
tion.29 Moreover, colitis could be exaggerated by
exogenous administration of recombinant IL23,29
while in another murine colitis model an anti-
IL23p19 antibody treated colitis.30
However, given that IL23p19-deficient mice are
highly susceptible to T cell-mediated colitis
induced by a hapten reagent,31 it is assumed that
selective neutralisation of IL23 may not be
beneficial under certain circumstances. Becker et
al revealed that dendritic cells (DCs) from IL23p19-
deficient mice produced elevated levels of IL12, and
that IL23 downregulates IL12 expression upon TLR
ligation.31 Interestingly, in vivo blockade of IL12p40
in IL23p19-deficient mice rescued mice from lethal
colitis,31 suggesting cross-regulation of IL12 expres-
sion by IL23 as a novel key regulatory pathway
during initiation of T cell-dependent colitis.32
Novel data also indicate that IL23 restrains Treg
activity to drive T cell-dependent colitis.33 The
Figure 1 Development of T helper (Th)1, Th2, Th17 and iTreg cells from naı¨ve CD4+ T
cells. Cytokines inducing the development of Th1, Th2, Th17 and iTreg cells are marked in
red. The main effector cytokines of these four cell lines are marked in blue. Cytokines
which inhibit the development of Th17 cells are marked in black. Although IL27 and
interferon c (IFNc) almost completely suppress the generation of Th17 cells by IL6 and
transforming growth factor b (TGFb), these cytokines only partially inhibit the expression
of retinoid-related orphan receptor-ct (RORct) by IL6 and TGFb.12 *Murine Treg cells but
not human Treg cells produce constitutively IL35, which has anti-inflammatory properties
and limits the expansion of Th17 cells. GATA, GATA binding protein; ICOS, inducible
co-stimulatory molecule; IL, interleukin; RUNX, runt-related transcription factor;
FOXP, forkhead box P3; STAT, signal transducer and activator of transcription;
T-bet, T box expressed in T cells.
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frequency of naı¨ve T cell-derived forkhead box P3
(FOXP3)+ cells in the colon increased in the
absence of IL23, indicating a role for IL23 in
controlling Treg induction.33 FOXP3-deficient T
cells induced colitis when transferred into recipi-
ents lacking IL23p19, showing that IL23 was not
essential for intestinal inflammation in the absence
of FOXP3.33 These data indicate that over-riding
immunosuppressive pathways is an important
function of IL23 in the intestine.
The findings of murine models of intestinal
inflammation are supported by findings in human
IBD. Studies in Crohn’s disease showed increased
IL12 and IL23 expression levels.34 35 Therefore, both
inhibiting Th1 cell-activating IL12 and Th17-
activating IL23 may have therapeutic potential.
In agreement with these observations, an anti-
IL12/IL23p40 antibody (directed against the com-
mon p40 subunit of IL12 and IL23) demonstrated
its clinical potential showing a high rate of
remission and clinical responses compared to
placebo.36 Ustekinumab, a similar antibody direc-
ted against the p40 subunit of IL12 and IL23,
induced clinical response in patients with moder-
ate-to-severe Crohn’s disease, especially in patients
previously given infliximab.37 Currently, there are
no clinical data on the efficacy of an antibody
specifically neutralising the IL23p19 unit in human
intestinal inflammation, but based on its efficacy
in murine intestinal inflammation,30 future trials
using such an antibody in patients with Crohn’s
disease are anticipated. This would also help to
clarify whether antagonising the Th1 mediator IL12
or neutralising Th17-specific IL23 is responsible for
the treatment success seen with the IL12/23p40
antibody which neutralises both cytokines.
Proinflammatory cytokines such as TNFa, IL6
and IL1b primarily released from macrophages and
DCs also play a major role in the perpetuation of
the intestinal inflammation in Crohn’s disease
resulting in an imbalance of pro- and anti-
inflammatory cytokines (fig 2). Th1 cells, as well
as Th17 cells, may contribute to the increased
expression of TNFa in Crohn’s disease,38 39 suggest-
ing that the strong anti-inflammatory effects of
anti-TNF antibodies in Crohn’s disease may also
contribute to their ability to limit Th17-mediated
inflammation. Interestingly, in patients with
Crohn’s disease, one study identified a unique
subset of CD14+ macrophages that contributed to
IFNc production rather than IL17 production by
lamina propria mononuclear cells (LPMCs) depen-
dent on IL23 and TNFa.40 The same group also
found significant IL17 mRNA upregulation in
lamina propria CD4+ cells from patients with
ulcerative colitis, while IFNc was increased in
Crohn’s disease41 arguing somewhat against the
concept that IL23 contributes only to Th17
cytokine production.
HUMAN TH17 AND TH17/TH1 CELLS AND THEIR
INVOLVEMENT IN THE IMMUNOPATHOLOGY OF
CROHN’S DISEASE
Although many studies analysed the role of Th17
cells in animal models of intestinal inflammation
and autoimmunity, there are only a few studies
investigating the role of Th17 cells in patients with
Crohn’s disease. We recently demonstrated an
increased number of T cells expressing retinoid-
related orphan receptor-ct (RORct), the master
transcription factor for Th17 cells, in the lamina
propria of patients with Crohn’s disease.42 Th17
cells were also isolated from inflamed lesions of
patients with Crohn’s disease by Pene et al.43
Similar to Th2 cells, Th1 cells negatively cross-
regulate the differentiation of Th17 cells (fig 1),
and mice lacking the Th1 transcription factor T-
bet are characterised by greater numbers of Th17
cells,44 which might be related to reduced IFNc
production, resulting in less inhibition of Th17 cell
development. However, a number of investigators
identified a subset of Th17 cells which may co-
produce the Th1 cytokine IFNc.45 46 This is
particularly prominent at sites of inflammation
such as active Crohn’s disease,45 This may suggest
that IFNc may not always downregulate IL17A
production and may contribute to the pathogenetic
and proinflammatory functions of Th17 cells,
although this hypothesis needs further investigation.
Two independent studies demonstrated Th17
cells in human peripheral blood and in the gut from
healthy individuals and patients with Crohn’s
disease.45 46 These two studies showed that these
cells are characterised by the expression of RORct,
IL23R and CCR6, whereas they lack CXCR3, a
chemokine receptor that is characteristic for Th1
cells45 46 (fig 3). The study by Annunziato et al
demonstrated IL17A-producing T cells in the gut,
including T cell populations which also expressed
both IL17A and IFNc, which they named ‘‘Th17/
Figure 2 The imbalance of pro- and anti-inflammatory cytokines in Crohn’s disease. In
patients with Crohn’s disease, proinflammatory T helper (Th)17 and Th1 cytokines
outweigh the effect of anti-inflammatory cytokines secreted by regulatory T cells (Treg).
Cytokines released by antigen presenting cells (APCs) following contact with microbial
products trigger the differentiation of Th1 and Th17 cells or have a direct proinflammatory
effect (eg, via secretion of tumour necrosis factor a (TNFa)). New evidence indicates that
interleukin (IL)23 may restrain regulatory T cell activity causing intestinal inflammation.33
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Th1’’ cells45 (fig 3). Acosta-Rodriguez et al identi-
fied Th17 cells to be characterised by
CCR6+CCR4+ expression, while CCR6+CXCR3+-
expressing Th1 cells also included a subset which
produced both IL17A and IFNc46 (fig 3). Moreover,
very recent findings implicate CD161 as a novel
surface marker for human Th17 cells and demon-
strate the exclusive origin of these cells from a
CD161+CD4+ T cell progenitor49 (fig 3). The
studies by Annuziato et al45 and by Acosta-
Rodriguez et al46 challenge the traditional concept
that IFNc suppresses Th17 and enhances Th1
development (fig 1). This is in line with a very
recent study demonstrating that IFNc triggers
APCs to produce IL1 and IL23 and enables them
to induce memory Th17 cell expansion.50
Therefore, the interactions between Th1 and
Th17 cells and the role of IFNc on Th17 cells
may be more complex than previously assumed
and require further analysis to delineate the
specific contributions of these cell lines to
Crohn’s disease and other autoimmune diseases.
TH17 CELL DIFFERENTIATION
In contrast to Th1 and Th2 cell differentiation,
which depend on their respective effector cytokines
(IFNc and IL4) for differentiation (fig 1), Th17 cells
do not require IL17 for their differentiation.
Murine Th17 cells originate from naı¨ve CD4+ T
cells in the presence of IL6 and TGFb and their
development is then amplified and stabilised by
IL21 and IL2351–53 (fig 4). RORct has been identified
as the master transcription factor guiding Th17
differentiation, which also synergises with other
transcription factors such as STAT3, RORa,
interferon regulatory factor (IRF)4 and runt-related
transcription factor (RUNX)1.54–57 IL23 promotes
maintenance but not commitment to the Th17
lineage.58
Initial studies demonstrated differences between
the development of murine and human Th17 cells. In
particular, it was questioned whether TGFb, which is
essential for the development of murine Th17 cells, is
also required for the development of human Th17
cells.59–61 However, very recently, TGFb in combina-
tion with IL1b, IL6 or IL21 was shown to induce the
differentiation of human Th17 cells,62 63 suggesting
no major differences between the differentiation of
mouse and human Th17 cells, although some aspects
were investigated in greater detail in murine Th17
cells (fig 4). The discrepancy between the different
studies regarding the effect of TGFb might be related
to its capacity to upregulate RORct and simulta-
neously to inhibit its ability to induce IL17 expres-
sion.62 Inflammatory cytokines relieve this inhibition
and increase RORct-directed IL17 expression.62
In addition to its role in Th17 differentiation,
TGFb induces the Treg-specific transcription factor
FOXP364 which is a key regulatory gene for the
development of Treg cells.65 Given that addition of
IL6 to TGFb inhibits the generation of Treg cells and
induces Th17 cells, a reciprocal relationship between
Treg cells and Th17 cells has been proposed.52 In
murine T cells, the vitamin A metabolite retinoic
acid is a key regulator in TGFb-induced T cell
differentiation.66 While retinoic acid inhibits the
Th17 cell-associated transcription factor RORct in
Th17 cell-inducing conditions, it promotes the
differentiation of TGFb-dependent Treg cells66–69
(fig 4). The reciprocal relationship between Treg
and Th17 cells is further supported by the fact that
IL2, which is a growth factor for Treg cells, inhibits
the generation of Th17 cells70 (fig 4). Similarly, the
aryl hydrocarbon receptor was identified as a ligand-
dependent system to control the generation of Th17
versus iTreg cells.71
THE ROLE OF INTESTINAL MICROBIOTA IN TH17
CELL DIFFERENTIATION
The development of intestinal Th17 cells is also
influenced by the gut microbial flora.72 In specific
pathogen-free mice, Niess et al demonstrated high
numbers of Th17 cells in the lamina propria of the
ileum and colon, areas which are typically affected
by Crohn’s disease.73 They demonstrated that the
microflora is required for the accumulation of
cytokine (IL17A, IFNc, TNFa, IL10)-producing
CD4+ T cells in the colonic lamina propria.73 In
agreement with this study, analysis of different
mouse strains performed in Dan Littman’s labora-
tory demonstrated that Th17 cell differentiation in
the lamina propria of the small intestine requires
specific commensal microbiota and is inhibited by
treating mice with selective antibiotics.74 The
Figure 3 Development of human T helper (Th)1, Th17 and Th17/Th1 cells from a
common CD161+CD4+ precursor cell. Human Th17 and Th17/Th1 cells, which show
features of both Th17 and Th1 cells, originate only from CD161+CD4+ T cell precursor
cells, while Th1 and Th2 cells can originate from both CD161+ and CD1612 T cells.
Essential for Th17 and Th17/Th1 cell development from CD4+CD161+ precursors is
exposure to antigen presenting cell (APC)-released IL23 and IL1b, while IL12 favours the
development of Th1 cells and IL4 the development of Th2 cells. Th17 cells are
characterised by surface expression of CCR6 and CCR4, while CCR6+CXCR3+-expressing
Th1 cells include a subset which produces both IL17A and IFNc (‘‘Th17/Th1 cells’’).
Another study demonstrated that human Th17 cells are identified as bearing the
CCR2+CCR52phenotype.47 This schematic drawing is based on a figure by Annunziato
et al48 and the results of the study by Acosta-Rodriguez et al.46 IFN, interferon;
IL, interleukin; TGF, transforming growth factor.
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absence of Th17 cell-inducing bacteria was accom-
panied by an increase in FOXP3+ Tregs in the
lamina propria.74 These results suggest that the
composition of intestinal microbiota regulates the
Th17:Treg balance in the lamina propria and may
thus influence intestinal immunity and tolerance
which is disturbed in Crohn’s disease.74 While some
bacteria favour Th17 cell development, certain
commensals and probiotics may limit uncontrolled
Th17 cell development. In germ-free mice, Zaph et
al demonstrated that the frequency of Th17 cells in
the large intestine is significantly elevated in the
absence of commensal bacteria.75 Commensal-
dependent expression of the IL17 family member
IL25 (IL17E) by intestinal epithelial cells limited
the expansion of Th17 cells in the intestine by
inhibiting expression of macrophage-derived IL2375
(figs 1 and 5). Certain commensals also limited
Th17 production in other studies.76 77
TH17 EFFECTOR CYTOKINES AS MEDIATORS OF
INTESTINAL INFLAMMATION
Wilson et al demonstrated that Th17 cells are
characterised by an increased expression of IL17A,
IL17F, IL22, IL26, IFNc and CCL20.60 Consistently,
we and others demonstrated an increased expres-
sion of IL17A,78 IL17F,79 IL22,80 81 IL2642 and
CCL2082 in active Crohn’s disease, supporting a
role for these cytokines and chemokines in the
disease pathogenesis. Given that the receptors for
IL17, IL22 and IL26 are expressed by intestinal
epithelial cells,42 80 83 Th17 cells exert a number of
biological functions on the intestinal barrier. An
overview of this complex interplay between Th17
cells and the intestinal barrier contributing to the
perpetuation of intestinal inflammation in Crohn’s
disease is given in fig 5. The specific roles of the
main Th17 effector cytokines on the intestinal
barrier and their role in intestinal inflammation are
discussed in the following sections.
Interleukins 17A and 17F
The main characteristic of Th17 cells is the
expression of IL17A and IL17F. Although IL17A is
mainly expressed by Th17 cells, other sources of
this cytokine including murine CD8+ cells,84 85
natural killer T cells (NKT),86 and cd T cells87 88
were also identified. IL17A is bound by the IL17
receptor A (IL17RA), which is expressed by
epithelial cells, endothelial cells and fibroblasts.89
IL17A activates nuclear factor kappa B (NF-kB) and
mitogen-activated protein kinase (MAPK) path-
ways.83 90 91 IL17-deficient mice have decreased
antigen-specific T cell activation and antibody
production.92 93 Fujino et al found an increased
expression of IL17A mRNA and intracellular
protein in the intestinal mucosa of patients with
IBD.78 Similarly, we demonstrated increased IL17F
mRNA expression levels in patients with active
Crohn’s disease.79 In colonic epithelial cells, IL17A
differentially regulates chemokine expression
(fig 6).94 In a model of trinitrobenzene sulfonic
acid (TNBS)-induced colitis, mice deficient in the
expression of the IL17 receptor IL17RA showed
reduced CXCL2 expression and reduced neutrophil
migration into the colon.95 Another recent study
demonstrated that IL17A and IL17F have a redun-
dant but highly pathogenic role in a murine model of
intestinal inflammation.96 Interestingly, IL17RA-
deficient mice also show defective granulocyte
colony stimulating factor (G-CSF) responses, and
defects in the granulopoiesis resulting in enhanced
susceptibility to experimental Klebsiella pneumoniae
pulmonary infection,97 suggesting that IL17RA
inhibition may increase the risk for infectious
complications. While the majority of IL17A-
mediated effects increase the inflammatory response
(fig 6), some studies indicate epithelial barrier
protective responses such as upregulation of anti-
microbial peptides98 and maintaining the epithelial
barrier by modulating tight junctions.99 Figure 6
gives an overview of the multiple functions of IL17A
which have been implicated in the perpetuation of
inflammation in Crohn’s disease. Efficacy and safety
studies with AIN457, a monoclonal anti-IL17 anti-
body, are under way for Crohn’s disease.100 The
outcomes of this study will help to uncover the
potential of specific targeting of IL17 for treating
Crohn’s disease.
Figure 4 Th17 cell differentiation in mice and humans. (A) Murine Th17 cells originate
from naı¨ve CD4+ T cells in the presence of TGFb (likely secreted by iTregs) and IL6
(secreted by APCs). Their development is then amplified by IL21 and stabilised by IL23.
Th17 cells secrete and respond to IL21 in an autocrine manner. IL12, IFNc, IL2, IL4, IL25,
IL27, IL35 and retinoid acid inhibit the development of murine Th17 cells. In contrast, the
presence of TGFb and retinoic acid or IL2 reciprocally favours the development of
tolerising, anti-inflammatory iTregs. (B) Human Th17 cells seem to originate in response
to the combined activity of IL1b and IL6, or the activity of IL1b or IL23 alone, whereas the
combined activity of IL1b and IL23 was not shown to have any additive or synergistic
effect. Addition of TGFb (*) to human naı¨ve or memory CD4+ T cells inhibited the
development of human Th17 cells in some earlier studies.59–61 However, very recently,
TGFb in combination with IL1b, IL6 or IL21 was shown to induce the differentiation of
human Th17 cells.62 63 This indicates that there are likely no major differences in the
differentiation of murine and human Th17 cells. Similar to murine Th17 cells, IL21 and
IL23 amplify and stabilise the development of human Th17 cells. IL23R and CCR6 are
surface markers of Th17 cells. APC, antigen presenting cell; IFN, interferon; IL, interleukin;
TGF, transforming growth factor; Th, T helper.
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Interleukin 22
The IL10-like cytokine IL22 was recently shown to
be expressed by Th17 cells98 101 102 and in subsets of
natural killer (NK) cells.103–107 The IL22 receptor
complex is composed of the specific subunit
IL22R1 and the IL10R2 subunit, which is also
shared with the receptors for IL10, IL26 and the
lambda-IFNs (IL28A, IL28B and IL29).42 80 108–111 We
recently demonstrated expression of the IL22
receptor complex in intestinal epithelial cells.80
IL22 receptor activation results in activation of
STAT3 and increased transcription of proinflam-
matory cytokines such as IL8 and TNFa80 (fig 7).
Similarly, the upregulation of proinflammatory
cytokines, chemokines and metalloproteinases
mediated via activation of NF-kB and AP-1 has
been shown in IL22-stimulated colonic subepithe-
lial myofibroblasts112 (fig 7).
In addition to its proinflammatory properties,
we demonstrated barrier protective functions for
IL22 including increased migration and prolifera-
tion of intestinal epithelial cells80 which we found
in other cell types including hepatocytes.113 114
These data are further supported by the genome-
wide search of potential downstream targets in IL22-
treated keratinocytes uncovering a large group of
genes involved in tissue repair and wound heal-
ing.115 116 Moreover, we and others found an increased
expression of protective defensins upon stimulation
with IL22.80 117 We recently demonstrated that
particularly b-defensin-2, which is transcriptionally
upregulated by IL22,80 promotes intestinal wound
healing.118 In addition to defensins, IL22 increases the
expression of a number of other epithelial protective,
antimicrobial peptides119 (fig 7).120 IL22 may also exert
protective effects in Crohn’s disease by increasing the
expression levels of lipopolysaccharide (LPS)-binding
protein (LBP), thereby antagonising circulating LPS
in these patients.121 A functional role for IL22 in
Crohn’s disease is further sustained by the increased
IL22 expression levels found in the serum and
intestine of patients with active Crohn’s dis-
ease.80 81 112 121 However, there is evidence that IL22
may play a role in ulcerative colitis. Andoh et al
demonstrated increased IL22 expression in active
ulcerative colitis although the expression levels were
lower than in Crohn’s disease.112 Similar observations
were made by our group.80 Moreover, IL22 exhibited
protective effects in a colitis model122 and a mouse
model of ulcerative colitis.119 Taken together, IL22
has bi-directional functions in Crohn’s disease.123
While it upregulates a number of proinflammatory
mediators, it also mediates intestinal barrier function
by increasing the expression of antimicrobial peptides
and upregulating proliferation and migration of
intestinal epithelial cells (fig 7).
Interleukin 26
In addition to IL17A, IL17F and IL22, human Th17
cells produce IL26,60 62 another IL10-like cytokine,
which is not expressed in mice. We demonstrated
the expression of the IL26 receptor complex
composed of IL20R1 and IL10R2 in intestinal
epithelial cells.42 IL26 activates MAP kinases,
serine/threonine protein kinase (Akt) and
STAT1/342 and the gene transcription of other
proinflammatory cytokines. However, in contrast
to the proliferative effects of IL22,80 it decreases cell
proliferation,42 thereby potentially impairing
intestinal wound healing. In inflamed colonic
lesions of patients with Crohn’s disease, we found
an elevated IL26 mRNA expression that correlated
highly with IL8 and IL22 expression levels.42
Immunohistochemical analysis demonstrated IL26
protein expression in colonic T cells including
RORct-expressing Th17 cells with an increased
number of colonic IL26-expressing cells in active
Crohn’s disease.42 IL26-expressing Th17 cells in the
intestinal mucosa of patients with Crohn’s disease
were also found in the study by Pene et al.43
Currently, the exact functional role of IL26 in
intestinal inflammation remains unclear and stu-
dies in murine models are limited by the lack of
endogenous IL26 expression in mice.
Interleukin 21
IL21 is another cytokine secreted by Th17 cells.124–126
IL21 expression is induced by IL6 in a STAT3-
dependent fashion.125 126 IL21 regulates the differen-
tiation of CD4+ T cells to Th17 cells in an autocrine
manner, thereby amplifying the Th17 cell response
and inducing its own expression in an autocrine loop
(fig 4).124–126 Enhanced IL21 expression was found in
Figure 5 Interactions between cytokines released from Th17 cells, APCs and intestinal
epithelial cells in Crohn’s disease. After activation of TLRs and NOD2 by bacterial
products, APCs secrete IL23, favouring the development of Th17 cells, and IL12, which is
essential for the development of Th1 cells. Commensal-dependent expression of IL25
(IL17E) by IECs limits the expansion of Th17 cells in the intestine by inhibiting expression
of APC-derived IL23. Th17 cells secrete a number of proinflammatory cytokines for which
receptors are expressed on IECs. IECs release in turn an array of proinflammatory
cytokines and chemokines such as CXCL8 attracting neutrophils and CCL20, which is
chemotactic for Th17 cells and DCs, further exacerbating the intestinal inflammation.
Certain Th17 cytokines such as IL22 have also epithelial barrier protective properties such
as increasing defensin secretion by Paneth cells, enhancing mucin production by goblet
cells, and promoting IEC migration, thereby limiting inflammation. (For details regarding
IL17A see fig 6; for details on IL22 see fig 7.) APCs, antigen presenting cells;
DCs, dendritic cells; IECs, intestinal epithelial cells; IL, interleukin; NOD, nucleotide
binding and oligomerisation domain; Th, T helper; TLR, toll-like receptor.
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Crohn’s disease,127 particularly in lamina propria
lymphocytes.128 Interestingly, the Th1 cytokine IL12
enhanced IL21 in normal lamina propria lympho-
cytes through an IFNc-independent mechanism, and
blocking of IL12 in lamina propria mononuclear cells
derived from patients with Crohn’s disease
decreased anti-CD3-stimulated IL21 expression.127
Neutralisation of IL21 in cultures of Crohn’s disease
lamina propria mononuclear cells decreased phos-
phorylated STAT4 and T-bet expression, thereby
inhibiting IFNc production.127 IL21 may therefore
contribute not only to Th17-mediated inflammation
but also to the ongoing Th1 mucosal response in
Crohn’s disease.127 Part of the proinflammatory
activities of IL21 seem to be mediated by an
increased production of matrix metalloproteinases
(MMPs) in fibroblasts.129 Interestingly, we recently
demonstrated that certain single nucleotide poly-
morphisms (SNPs) in the IL2/IL21 gene region are in
epistasis with IL23R gene variants regarding suscept-
ibility to ulcerative colitis130 (see details below).
The chemokine CCL20
The chemokine CCL20 has been shown to be
another effector protein of Th17 cells.60 CCL20 is
the ligand to CCR6, which is expressed on the
surface of Th17 cells. Therefore, Th17 cell-expressed
CCL20 may contribute in an autocrine loop to
accumulation of Th17 cells and perpetuation of the
intestinal inflammation in Crohn’s disease (figs 5
and 6). Consistently, we recently demonstrated
increased CCL20 expression in patients with
Crohn’s disease which correlated with IL8 mRNA
expression.82 In mice, a neutralising monoclonal
antibody directed against CCL20 protected against
TNBS-induced colitis.131
THE INFLUENCE OF SUSCEPTIBILITY GENES OF
CROHN’S DISEASE ON IL23R SIGNALLING AND
TH17 CELL DEVELOPMENT
The role of Th17 cells in the pathogenesis of
Crohn’s disease is strongly supported by the results
of recent genome-wide association studies impli-
cating IL23R and signal transducers downstream of
IL23R in the genetic susceptibility to Crohn’s
disease. An overview of the most important
susceptibility genes for Crohn’s disease and how
they contribute to Th17 cell development is given
in the following sections.
Interleukins 23R and 12B
The first genome-wide association study in the
North American population demonstrated that an
uncommon coding variant in the IL23R gene
(rs11209026, c.1142G.A, p.Arg381Gln) confers
strong protection against Crohn’s disease, and
additional non-coding IL23R variants are indepen-
dently associated.9 This finding has been confirmed
by a number of investigators including our
group.132 Importantly, IL23R is also associated to
a lesser degree with ulcerative colitis.9 132 In
contrast to the majority of IBD susceptibility
genes identified so far, the minor allele of the
IBD-associated IL23R SNPs may modulate the IBD
risk in different directions. While some variants
(eg, rs11209026, p.Arg381Gln) decrease IBD sus-
ceptibility, others (eg, rs1004819) increase IBD
susceptibility. Currently, it is unknown how these
IL23R SNPs exactly modulate IBD susceptibility,
although the leading hypothesis is that the IL23R
signalling pathway contributes to IBD by promot-
ing a pro-inflammatory state133 (fig 8). Our group
demonstrated that patients with Crohn’s disease
and with IBD risk-increasing IL23R variants have
higher IL22 serum levels than patients with IBD
risk-decreasing IL23R variants.81 Although IL22 has,
in addition to its proinflammatory functions,
barrier-protective properties80 119 (fig 7), IL22 serum
levels correlate with Crohn’s disease activity,81 121
suggesting that IL22 contributes (likely via IL23R)
to the pathogenesis of Crohn’s disease. However,
so far it is unknown if IL23R variants also
modulate the secretion of other Th17 cytokines.
In another recent study, certain IL23R variants
(including p.Arg381Gln) were retrovirally trans-
duced into human T cell blasts and functionally
characterised by measuring the IL23-induced
signal transduction pathways, and IFNc and IL10
production.134 However, no differences were
detected between the genetic variants and wild-type
Figure 6 The multiple effects of the main Th17 cytokine IL17A on the perpetuation of
inflammation in Crohn’s disease. IL17A is the main cytokine released by Th17 cells and
exerts a number of proinflammatory effects on intestinal epithelial cells, endothelial cells,
macrophages, fibroblasts and colonic myofibroblasts through increased release of
proinflammatory chemokines, cytokines and other proinflammatory mediators such as
prostaglandins, MMPs, NOS-2 and G-CSF. This results in recruitment and accumulation of
granulocytes, lymphocytes and DCs and further perpetuation of the inflammatory
response by increasing the production of proinflammatory cytokines and chemokines.
However, there is also evidence that IL17A (particularly in combination with IL22) may
enhance the production of antimicrobial peptides such as defensins in Paneth cells.
DCs, dendritic cells; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte
macophage colony stimulating factor; IL, interleukin; MMPs, matrix metalloproteinases;
MUC, mucin; NOS-2, nitric oxide synthase-2; TNF, tumour necrosis factor.
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regarding the function of the IL23R chain.134 Patients
with Crohn’s disease are more likely to develop other
autoimmune diseases including ankylosing spondy-
litis, psoriasis and rheumatoid arthritis.
Interestingly, for these diseases, an association with
IL23R has also been established by genome-wide
association scans.135–137
The important role of IL23R in the pathogenesis
of Crohn’s disease is further supported by the
findings of a large meta-analysis of the first three
genome-wide association studies.8 Among the
more than 30 regions with the highest association
signal with Crohn’s disease, four SNPs are within
genes with a major role in IL23R signalling (IL23R,
IL12B, STAT3 and JAK2) (fig 8).8 Two other
susceptibility genes for Crohn’s disease (CCR6,
TNFSF15)8 are also involved in Th17 differentia-
tion (figs 8 and 9). Interestingly, significant
disease associations with IL23R, IL12B, STAT3
and JAK2 have also been demonstrated in ulcera-
tive colitis.9–11 132 138 IL12B encodes the IL12/IL23
subunit p40, which is part of both IL12 and IL23
(fig 8) further demonstrating the difficulty in
differentiating the association of this susceptibility
gene with Th1 versus Th17 signalling components.
STAT3 and JAK2
STAT3 is not only a downstream signalling
component of IL23 but is also activated by a
number of other cytokines including IL6, IL10,
IL21, IL22, IL26 and IL31,42 80 113 114 139 suggesting a
more complex role of STAT3 in the pathogenesis of
IBD which is further supported by both pro- and
anti-inflammatory properties of STAT3. This bi-
directional effect of STAT3 in intestinal inflamma-
tion is supported by the fact that activated STAT3
has been found in human IBD and murine colitis
models,140 141 while STAT3 deletion during haema-
topoiesis causes a Crohn’s-like disease in mice.142
An earlier study, which was performed before
establishing the concept of Th17 cells, demon-
strated that STAT3 deficiency in macrophages and
neutrophils results in enhanced Th1 activity and
spontaneous enterocolitis in mice.143 However, a
recent study showed that mutations in STAT3
impair the development of human Th17 cells.144
Similar to STAT3, JAK2, a gene encoding an IL23R
signalling component up-stream of STAT3, has
been shown to be associated with Crohn’s disease8
but also with ulcerative colitis.10
The chemokine receptor CCR6
CCR6, the gene encoding the chemokine receptor
CCR6, has been identified in the meta-analysis by
Barrett et al as another susceptibility gene of
Crohn’s disease.8 CCR6 is the receptor for the
chemokine CCL20, for which we demonstrated an
increased expression in active Crohn’s disease.82 A
marked increase in the number of CCR6-bearing
lamina propria CD4+ and CD8+ T cells was
observed in TNBS-treated animals,131 implicating
CCR6+ T cells as mediators of intestinal inflam-
mation. Several studies indicated CCR6 as a
surface marker of Th17 cells,43 45 145–149 suggesting
that the genetic susceptibility of Crohn’s disease
modulated by variants in the CCR6 gene may be
mediated via modulation of Th17 function (fig 8).
However, the functional consequences of CCR6
gene variants associated with Crohn’s disease have
not been studied yet.
TNFSF15
TNFSF15 encodes TL1A, which is a TNF-like
molecule that mediates co-stimulation of Th1
and Th17 cells. Several studies, including the
meta-analysis of genome-wide association studies,
confirmed TNFSF15 as susceptibility gene for
Crohn’s disease.8 150 151 Expression of TL1A is
increased in the mucosa of Crohn’s disease patients
and murine models of ileitis.152–154 An anti-TL1A
antibody prevented chronic colitis and attenuated
established colitis by downregulation of both Th1
and Th17 activation155 (figs 8 and 9). TL1A-
deficient DCs exhibit reduced capacity in support-
ing Th17 differentiation and proliferation.156
Therefore, TL1A is required for the optimal
differentiation as well as effector function of
Th17 cells (fig 8).156
Interleukins 17A, 17F, 22 and 26
The meta-analysis of the first genome-wide asso-
ciation studies did not reveal any SNPs within
the IL17A and IL17F genes among the most
significantly associated Crohn’s disease suscept-
ibility loci. However, there are some studies
Figure 7 The proinflammatory and epithelial barrier protective properties of the Th17
cytokine IL22 with divergent effects in the pathogenesis of Crohn’s disease. IL22,
produced in Th17 cells and subsets of natural killer cells (NKp46), has both
proinflammatory properties (mediated via increased secretion of proinflammatory
cytokines and chemokines from intestinal epithelial cells and colonic subepithelial
myofibroblasts) but also epithelial barrier protective functions mediated by enhancing
migration and proliferation of intestinal epithelial cells and the release of antimicrobial
peptides from Paneth cells and mucins from goblet cells. AP, activator protein-1;
IECs, intestinal epithelial cells; IL, interleukin; LBP, lipopolysaccharide (LPS)-binding
protein; LIF, leukaemia inhibitory factor; MMPs, matrix metalloproteinases; MUC, mucin;
NF-kB, nuclear factor kappa B; Reg, regenerating islet derived (protein); STAT, signal
transducer and activator of transcription; Th, T helper; TNF, tumour necrosis factor.
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demonstrating certain effects of these genes on the
susceptibility and phenotype of IBD. A Japanese
study demonstrated an influence of certain IL17A
and IL17F SNPs on ulcerative colitis susceptibility
and the ulcerative colitis phenotype.158 However,
our group did not observe significant differences
regarding genotype frequencies of the IL17F
p.His161Arg SNP between healthy controls and
IBD patients.79 A North American study demon-
strated an interaction between IL23R and IL17A and
between IL23R and IL17RA haplotypes regarding
susceptibility to Crohn’s disease.159 They found
associations of IL17RA with both Crohn’s disease
and ulcerative colitis, while IL17A appeared to be
specific for Crohn’s disease.160 A very recent genome-
wide association study demonstrated an association
of a SNP within the IL26 gene with susceptibility to
ulcerative colitis, while other SNPs within proximity
to the IL22/IL26 gene cluster were also associated
with ulcerative colitis;171 however, their effect in
Crohn’s disease is currently unclear.
Interleukins 2 and 21
IL2 and IL21 may also influence IL23 signalling
(fig 8). While IL21 synergises with IL23 to activate
STAT3 and Th17 cell differentiation, IL2 inhibits
STAT3 signalling (and Th17 cell development) via
STAT5 activation, thereby reciprocally favouring
Treg development (figs 4 and 8). We recently
demonstrated that SNPs within the KIAA1109/
TENR/IL2/IL21 linkage disequilibrium block on
chromosome 4q27 had a protective effect on
susceptibility to ulcerative colitis.130 Importantly,
in ulcerative colitis, epistasis was observed between
the IL23R SNP rs1004819 and three SNPs in the
KIAA1109/TENR/IL2/IL21 block (rs13151961,
rs13119723 and rs6822844).130 Interestingly, SNPs
within the chromosome 4q27 region were also
found to be associated with other autoimmune
diseases including coeliac disease, rheumatoid
arthritis, type 1 diabetes, Graves’ disease and
psoriatic arthritis,136 167–169 suggesting a common
genetic background for these autoimmune diseases.
Figure 8 Proteins, which are encoded by susceptibility genes for Crohn’s disease and ulcerative colitis, involved in
IL23R signalling and Th17 cell development. The figure highlights genes encoding signalling components in Th17 cells,
which were found to be associated with Crohn’s disease and partially also with ulcerative colitis. The proteins encoded
by genes found to be associated with Crohn’s disease in genome-wide association studies are highlighted in red.
Similarly, the genes encoding IL23R, IL12/23 p40, JAK2, and STAT3 were also found to be associated with ulcerative
colitis in genome-wide studies. *Recently, we demonstrated an association of SNPs within the IL2/IL21 genes (proteins
marked in dark blue) with ulcerative colitis which are in epistasis with the IL23R gene.130 **A very recent genome-wide
scan demonstrated an association with susceptibility to ulcerative colitis for SNPs in and within the proximity of the
IL22/IL26 gene cluster.157 ERK, extracellular signal-regulated kinase; FOXP3, forkhead box P3; IL23R, interleukin 23
receptor; IRF, interferon regulatory factor; JAK2, Janus kinase 2; NF-kB, nuclear factor kappa B; ROR, retinoid-related
orphan receptor; RUNX, runt related transcription factor; SNP, single nucleotide polymorphism; STAT, signal transducer
and activator of transcription; Th, T helper; TNF, tumour necrosis factor; TNFRSF, TNF receptor superfamily 25;
TNFSF, TNF superfamily; TYK, tyrosine kinase;
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NOD2/CARD15, TLR4 and TLR9
NOD2/CARD15 is the most important and most
often replicated susceptibility gene for Crohn’s
disease which was also confirmed in the first meta-
analysis of genome-wide association studies.8
Interestingly, DCs activated by the NOD2 ligand
muramyl dipeptide (MDP) induce the production
of IL17A and promote Th17 cell development via
IL23 secretion (fig 9).170 DCs with Crohn’s disease-
associated NOD2 mutations have reduced capacity
to induce enhanced levels of IL17A when primed
with TLR ligands.170 Similarly, we recently demon-
strated that monocytes from individuals with two
mutated NOD2 alleles displayed an impaired
release of TNFa and IL10 but also of IL1b and
IL12/IL23p40 in response to MDP.171 Interestingly,
monocytes from patients with Crohn’s disease
with two mutated NOD2 alleles displayed sig-
nificantly higher basal levels of IL12/IL23p40 in cell
culture supernatants compared to wild-type
Crohn’s disease patients and control individuals,171
suggesting increased baseline IL12/IL23 activity in
patients with NOD2 mutations. The increased
baseline IL12/IL23 activity could be an underlying
mechanism of the chronic mucosal inflammation
seen in Crohn’s disease, particularly in patients
with two NOD2 mutations, especially the
p.Leu1007fsX1008 variant.172 173 Therefore, NOD2
mutations may contribute to DC dysfunction,170
resulting in Crohn’s disease although a number of
other mechanisms including decreased defensin
production are under consideration (fig 9).174 175
Consistent with the reduced defensin expression,
intestinal epithelial cells expressing mutated
NOD2 have a reduced capacity to restrict prolif-
eration of bacterial pathogens in monolayer cul-
tures,176 raising the possibility that NOD2
mutations may increase the bacterial colonisation
of the intestine resulting in increased DC activa-
tion and IL23-driven Th17 responses.
In a large meta-analysis, gene variants in TLR4,
another pattern recognition receptor which med-
iates LPS signalling, were found to be associated
with Crohn’s disease but not with ulcerative
colitis.166 However, this finding has not yet been
confirmed in genome-wide association scans. In
addition, we demonstrated that the TLR4
p.Asp299Gly and p.Thr399Ile variants were parti-
cular strong predictors for a stricturing phenotype
in Crohn’s disease,177 TLR4 activation induces both
IL12/IL23p40 and IL12p35 mRNA expression,178
suggesting that bacterial LPS may trigger both
Th1 and Th17 immune responses.
We recently demonstrated epistasis between
TLR9 SNPs and IL23R SNPs as well as NOD2
mutations regarding susceptibility to Crohn’s
disease,179 suggesting that TLR9, a gene encoding
a receptor for bacterial DNA, modulates IL23R-
mediated effects on susceptibility to Crohn’s
disease. Of interest, Tlr92/2 mice display increased
frequencies of Treg cells within intestinal effector
sites and reduced constitutive Th17 and Th1
effector cells (Teff).182 These data complement the
recent findings by Dan Littman’s group74 and
suggest that commensal DNA is a natural adjuvant
for priming intestinal responses via modulation of
the Treg/Teff cell equilibrium.180
ATG16L1, IRGM, and PTGER4 expression
modulating SNPs in 5p13.1
With the exception of NOD2 and IL23R, ATG16L1
is the most commonly replicated susceptibility
gene for Crohn’s disease.8 181–183 Similar to IRGM,
another susceptibility gene for Crohn’s disease,184
ATG16L1 is essential for autophagy of bacteria.182 185
Figure 9 The main groups of susceptibility genes for Crohn’s disease and their effect on
Th17 cell development. This figure gives an overview of how the main susceptibility
genes for Crohn’s disease participate in the development of Th17 cells. The recognition of
bacterial products by APCs depends on pattern recognition receptors such as NOD2 and
TLR4. Bacterial products are phagocytosed by APCs, a process that, in the terminal
ileum, is also highly dependent on the expression of the chemokine receptor CX3CR1,161
which responds to epithelial cell-expressed fractalkine.162 163 Following phagocytosis,
bacteria undergo autophagy which is dependent on the autophagy genes ATG16L1 and
IRGM. ATG16L1 may also influence interleukin (IL)1b and IL18 secretion in APCs.
Activated APCs secrete IL23, IL6 and IL1b, which inhibit Treg development but are
necessary for Th17 cell differentiation, while IL12, also secreted by antigen-stimulated
APCs, triggers the development of Th1 cells. Th17 cells produce cytokines such as IL17A
and IL22, which act on the intestinal barrier stimulating the release of defensins (from
Paneth cells), mucins (from goblet cells), and prostaglandins. IL22 also modulates
intestinal barrier function. Defensin secretion from Paneth cells is additionally modulated
by Crohn’s disease-associated NOD2 and ATG16L1 mutations. On the other hand, b-
defensin-2 has also be shown to be a ligand to TLR4164 and CCR6.165 Prostaglandin E2
binds to its receptor PTGER4 and, together with bacterial products (recognised by pattern
recognition receptors such as NOD2 and TLR4), promotes the release of IL23 from
dendritic cells. PTGER4 expression-modulating single nucleotide polymorphisms (SNPs)
are also associated with Crohn’s disease. PTGER4 is essential for maturation and
migration of certain APC subpopulations. SNPs in or within proximity of MUC19 encoding
mucins and ICOSL, the ligand for ICOS, have also been shown to be associated with
susceptibility to Crohn’s disease. Furthermore, the Crohn’s disease susceptibility gene
TNFSF15 encodes TL1A, which is a tumour necrosis factor-like molecule expressed by
intraepithelial lymphocytes which binds to DR3 (TNFRSF25) and mediates strong co-
stimulation of Th1 and Th17 cells. Genes marked with one asterisk were confirmed in the
meta-analysis by Barrett et al.8 The gene marked with two asterisks (TLR4) has been
shown to be a Crohn’s disease susceptibility gene in a large meta-analysis.166
APCs, antigen presenting cells; DR3, death receptor 3; ICOS, inducible co-stimulatory
molecule; IL, interleukin; NOD, nucleotide binding and oligomerisation domain;
PTGER4, prostaglandin receptor EP4; SNP, single nucleotide polymorphism; Th, T helper;
TL1A, TNF-like molecule 1A (TNF, tumour necrosis factor); TLR, toll-like receptor;
TNFRSF25, TNF receptor superfamily 25; Treg, regulatory T cell.
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In addition, knockout of ATG16L1 results in Paneth
cell dysfunction186 and enhances endotoxin-induced
IL1b production187 (fig 9). So far, a direct influence of
autophagy genes on Th17 cell development has not
been shown, although a defect autophagy of bacteria
may influence APC function, which could modulate
production of essential cytokines required for Th17
differentiation such as demonstrated for IL1b.187
Another group of susceptibility loci found to be
associated with Crohn’s disease relates to prosta-
glandin E2 signalling. A Belgian–French genome-
wide association study demonstrated that certain
SNPs in a gene desert on chromosome 5p13.1 are
strongly associated with susceptibility to Crohn’s
disease;188 specifically, this study found an associa-
tion between SNPs in this chromosomal region
modulating the expression of the prostaglandin
receptor EP4 (PTGER4) with the disease suscept-
ibility.188 We recently confirmed that SNPs in the
5p13.1 region associated with PTGER4 expression
are associated with Crohn’s disease.189 Importantly,
we found evidence for strong epistasis between
this region and several SNPs within the ATG16L1
gene regarding susceptibility to Crohn’s disease.189
Currently, it is unknown how these SNPs in the
5p13.1 region influence the pathogenesis of
Crohn’s disease. However, it is likely that these
effects are mediated via the PTGER4 ligand
prostaglandin E2 and via DC dysfunction190 (fig 9).
It may be hypothesised that such a DC dysfunc-
tion could be further exacerbated by defects in the
autophagy pathway; eg, by mutations in
ATG16L1, which would explain the strong epistasis
between the 5p13.1 region and ATG16L1 found in
our study.189 Importantly, a recent study showed
that the proinflammatory effect of prostaglandin
E2 in an experimental IBD model is mediated
through the IL23–IL17 axis.191 In the presence of
exogenous prostaglandin E2, peripheral blood
mononuclear cells produced higher IL17A, CCL20
and CXCL8, and lower IFNc levels than in control
cultures.192 Exogenous prostaglandin E2 and IL23
synergised in inducing IL17A.192 However, prosta-
glandin E2 has also been implicated in the
induction of Tregs193 and in their suppressive
capacity194 suggesting that, similar to TGFb,
prostaglandin E2 may have a bi-directional influ-
ence on T cell differentiation depending on the
predominant cytokine environment. Figure 9 sum-
marises how the different susceptibility genes for
Crohn’s disease may collectively contribute to the
pathogenesis of Crohn’s disease.
ULCERATIVE COLITIS: ANOTHER TH17-MEDIATED
DISEASE?
There is good evidence that ulcerative colitis is
characterised by an exaggerated Th2-like response
as demonstrated by increased production of Th2
cytokines such as IL5 and IL13 in this disease.3 5 19
However, the fact that five genes involved in
downstream signalling of IL23 (IL23R, IL12B, JAK2,
STAT3, IL26) mediate susceptibility to ulcerative
colitis suggests strongly that Th17 cells are also
involved in its pathogenesis.9–11 132 157 Previously, it
has been assumed that Th17 cells do not con-
tribute to the pathogenesis of Th2 disorders since
IL4 and IL25 are both potent inhibitors of Th17
development.195 However, Kobayashi et al demon-
strated a significant upregulation of IL17A in
lamina propria CD4+ T cells following IL23
stimulation in ulcerative colitis.41 Upregulated
IL23p19 mRNA expression correlated with
IL17A.41 Similarly, we and others found high
expression levels of the Th17 cytokines IL17A,
IL22 and IL26 not only in inflamed colonic lesions
of patients with Crohn’s disease but also in active
ulcerative colitis.42 78 80 112 Taken together, these
findings suggest that Th17 cells also modulate
the predominant Th2-mediated inflammation in
ulcerative colitis.
CONCLUSIONS
The previous Th1/Th2 paradigm indicating pre-
dominant Th1-mediated responses in Crohn’s
disease and an exaggerated Th2-like inflammation
in ulcerative colitis has to be revised and updated
with the discovery of Th17 cells and Treg cells.
While Th17 cells contribute to intestinal inflam-
mation in both forms of IBD, particularly in
Crohn’s disease, Treg cells have tolerising, anti-
inflammatory properties. The results of the recent
genome-wide association studies, implicating genes
encoding downstream signalling components of
IL23 signalling in the disease susceptibility of
Crohn’s disease and ulcerative colitis, clearly
indicate that IL23R-expressing Th17 cells may play
a role in both forms of IBD.
Given that both the Th1 cytokine IL12 and the
Th17 modulator IL23 contain the p40 cytokine
subunit, a number of inflammatory activities
previously ascribed to IL12 may have been
mediated by IL23 and the role of Th1 cells in the
pathogenesis of Crohn’s disease may have been
overestimated. Nevertheless, the current evidence
suggests that both Th1 and Th17 cells contribute
to intestinal inflammation in Crohn’s disease, in
which even a third subpopulation of T cells
(‘‘Th17/Th1 cells’’), sharing features of both Th1
and Th17 cells, can be found. Key cytokines
involved in the differentiation of Th17 cells are
IL1b, IL6, TGFb, IL21 and IL23. TGFb reciprocally
regulates Treg differentiation under the influence
of IL2 and retinoid acid, while it favours Th17 cell
development in the concomitant presence of
proinflammatory cytokines. RORct is the key
transcription factor for Th17 cells. Bacteria and
probiotics may modulate Th17 cell development.
Considering that IL23 and IL12, two cytokines
essential for Th17 and Th1 development, are
produced in APCs after contact with bacteria and
bacterial products, it is likely that the exaggerated
T cell response in Crohn’s disease is rather a
secondary result caused by a primary barrier defect
in genetically susceptible individuals with subse-
quent bacterial invasion and APC activation.
IL17A, IL17F, IL21, IL22, IL26 and CCL20 are the
main effector cytokines and chemokines of human
Th17 cells. For most of these cytokines, receptors
Recent advances in basic science
1162 Gut 2009;58:1152–1167. doi:10.1136/gut.2008.163667
 group.bmj.com on April 24, 2013 - Published by gut.bmj.comDownloaded from 
are expressed on intestinal epithelial cells and
exposure to Th17 cytokines exaggerates the
inflammatory response by amplifying the secretion
of proinflammatory cytokines, chemokines, MMPs
and prostaglandins. Th17 cells also secrete some
amounts of TNFa and IL6. Recent evidence
suggests that anti-TNF treatment strategies inhibit
inflammatory DC cytokine production and
maturation, leading to reduced Th17 cell activ-
ity.196 An anti-IL12/23p40 antibody, which inhibits
both IL12-triggered Th1 inflammation and IL23-
mediated Th17 responses, has been successfully
applied in patients with Crohn’s disease.36 37
However, the clear contributions of inhibiting
Th1 and Th17 responses in Crohn’s disease can
only be analysed with an antibody inhibiting the
IL23 specific p19 subunit which demonstrated anti-
inflammatory properties in a murine colitis
model.30 The effector cytokines IL17A, IL17F,
IL21, IL22 and IL26, and the chemokine CCL20
are potential future therapeutic targets. Studies
targeting IL17 in Crohn’s disease are on the way,100
and an anti-CCL20 antibody demonstrated clinical
efficacy in a murine colitis model.131 However,
IL22, in particular, seems to mediate both proin-
flammatory as well as epithelial barrier protective
responses80 and murine models of inflammation
suggested even anti-inflammatory, protective
effects of IL22 in colitis.119 122 Therefore, further
understanding and characterisation of the IL23–
IL17 pathway and the numerous biological effects
it mediates is needed. Novel treatment strategies
have to clarify if it is necessary to inhibit the entire
IL23/Th17 axis through blockade of IL23, or if it is
more efficacious and safer to target select Th17 cell
products such as IL17A.
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